Loading...
What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
A relevant issue on the treatment of adrenocortical carcinoma (ACC) concerns the optimal duration of adjuvant mitotane treatment. We tried to address this question, assessing whether a correlation exists between the duration of adjuvant mitotane treatment and recurrence-free survival (RFS) of patien...
Na minha lista:
| Udgivet i: | J Pers Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8066814/ https://ncbi.nlm.nih.gov/pubmed/33916613 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jpm11040269 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|